{"id":11060,"date":"2025-04-21T11:38:00","date_gmt":"2025-04-21T09:38:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=11060"},"modified":"2025-08-08T11:44:20","modified_gmt":"2025-08-08T09:44:20","slug":"management-of-refractory-checkpoint-inhibitor-induced-colitis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/","title":{"rendered":"Management of refractory checkpoint inhibitor-induced colitis"},"content":{"rendered":"
\n

Anas Zaher<\/a>\u00a01<\/a><\/sup>,\u00a0Maria Julia Moura Nascimento Santos<\/a>\u00a02<\/a><\/sup>,\u00a0Hassan Elsaygh<\/a>\u00a03<\/a><\/sup>,\u00a0Stephen J Peterson<\/a>\u00a01<\/a><\/sup>,\u00a0Carolina Colli Cruz<\/a>\u00a02<\/a><\/sup>,\u00a0Anusha Shirwaikar Thomas<\/a>\u00a02<\/a><\/sup>,\u00a0Yinghong Wang<\/a>\u00a02<\/a><\/sup><\/p>\n<\/div>\n\n

\n

Expert Opin Drug Saf.\u00a02025 Apr 21:1-10.\u00a0doi: 10.1080\/14740338.2025.2496431.\u00a0Online ahead of print.<\/p>\n<\/div>\n\n

\n

Introduction: <\/strong>This review discusses the epidemiology, pathophysiology, and factors associated with refractory immune-mediated diarrhea and colitis (r-IMDC), emphasizing tailored treatment strategies.<\/p>\n<\/div>\n\n

\n

Areas covered: <\/strong>The current literature on r-IMDC was reviewed using PubMed (2015-2025), focusing on clinical trials, meta-analyses, and case reports relevant to its management.<\/p>\n<\/div>\n\n

\n

Expert opinion:\u00a0<\/strong>Effectively managing r-IMDC is crucial for balancing toxicities and antitumor response. Available second and third-line management options for r-IMDC cases must be carefully evaluated. Future perspectives include development of standardized protocols beyond second-line therapies and predictive biomarkers to enable personalized treatment.<\/p>\n<\/div>\n\n

\n
    \n
  • ICIs are essential in cancer therapy but often cause IMDC, with up to 41% of patients developing steroid-refractory cases.<\/li>\n\n\n\n
  • Current guideline-recommended second-line therapies, such as infliximab and vedolizumab, fail in 11% of IMDC cases, underscoring the need for third-line interventions.<\/li>\n\n\n\n
  • Emerging therapies, including Janus kinase inhibitors, fecal microbiota transplantation, and interleukin-targeting agents, show promise for r-IMDC management. Also gma, IVIG.<\/li>\n\n\n\n
  • Personalized management strategies, incorporating gut microbiota modulation and targeted immune suppression, could improve outcomes in refractory colitis.<\/li>\n\n\n\n
  • Effective management of r-IMDC is critical for reducing prolonged immunosuppression, minimizing cancer treatment interruptions, and improving patient quality of life.<\/li>\n<\/ul>\n<\/div>","protected":false},"excerpt":{"rendered":"

    Anas Zaher\u00a01,\u00a0Maria Julia Moura Nascimento Santos\u00a02,\u00a0Hassan Elsaygh\u00a03,\u00a0Stephen J Peterson\u00a01,\u00a0Carolina Colli Cruz\u00a02,\u00a0Anusha Shirwaikar Thomas\u00a02,\u00a0Yinghong Wang\u00a02 Expert Opin Drug Saf.\u00a02025 Apr 21:1-10.\u00a0doi: 10.1080\/14740338.2025.2496431.\u00a0Online ahead of print. Introduction: This review discusses the epidemiology, pathophysiology, and factors associated with refractory immune-mediated diarrhea and colitis (r-IMDC), emphasizing tailored treatment strategies. Areas covered: The current literature on r-IMDC was reviewed using PubMed (2015-2025), […]<\/p>\n","protected":false},"template":"","scientific_tags":[781,532,424,878,691,461,464],"class_list":["post-11060","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-enterocolitis","scientific_tags-expert-opinion","scientific_tags-gma","scientific_tags-ici","scientific_tags-immune-checkpoint-inhibitors","scientific_tags-refractory","scientific_tags-treament"],"acf":[],"yoast_head":"\nManagement of refractory checkpoint inhibitor-induced colitis - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Management of refractory checkpoint inhibitor-induced colitis - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Anas Zaher\u00a01,\u00a0Maria Julia Moura Nascimento Santos\u00a02,\u00a0Hassan Elsaygh\u00a03,\u00a0Stephen J Peterson\u00a01,\u00a0Carolina Colli Cruz\u00a02,\u00a0Anusha Shirwaikar Thomas\u00a02,\u00a0Yinghong Wang\u00a02 Expert Opin Drug Saf.\u00a02025 Apr 21:1-10.\u00a0doi: 10.1080\/14740338.2025.2496431.\u00a0Online ahead of print. Introduction: This review discusses the epidemiology, pathophysiology, and factors associated with refractory immune-mediated diarrhea and colitis (r-IMDC), emphasizing tailored treatment strategies. Areas covered: The current literature on r-IMDC was reviewed using PubMed (2015-2025), […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-08T09:44:20+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/\",\"name\":\"Management of refractory checkpoint inhibitor-induced colitis - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2025-04-21T09:38:00+00:00\",\"dateModified\":\"2025-08-08T09:44:20+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Management of refractory checkpoint inhibitor-induced colitis - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/","og_locale":"es_ES","og_type":"article","og_title":"Management of refractory checkpoint inhibitor-induced colitis - Adacyte","og_description":"Anas Zaher\u00a01,\u00a0Maria Julia Moura Nascimento Santos\u00a02,\u00a0Hassan Elsaygh\u00a03,\u00a0Stephen J Peterson\u00a01,\u00a0Carolina Colli Cruz\u00a02,\u00a0Anusha Shirwaikar Thomas\u00a02,\u00a0Yinghong Wang\u00a02 Expert Opin Drug Saf.\u00a02025 Apr 21:1-10.\u00a0doi: 10.1080\/14740338.2025.2496431.\u00a0Online ahead of print. Introduction: This review discusses the epidemiology, pathophysiology, and factors associated with refractory immune-mediated diarrhea and colitis (r-IMDC), emphasizing tailored treatment strategies. Areas covered: The current literature on r-IMDC was reviewed using PubMed (2015-2025), […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/","og_site_name":"Adacyte","article_modified_time":"2025-08-08T09:44:20+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/","name":"Management of refractory checkpoint inhibitor-induced colitis - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2025-04-21T09:38:00+00:00","dateModified":"2025-08-08T09:44:20+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/management-of-refractory-checkpoint-inhibitor-induced-colitis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/11060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=11060"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=11060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}